Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ralph P Mason

Showing results (131-140 of 139) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 139 results.
Journal of Magnetic Resonance Imaging : JMRI|March 30, 2019
Translating preclinical MRI methods to clinical oncologyDavid A Hormuth, Anna G Sorace, John Virostko, et al.
RSC Medicinal Chemistry|September 10, 2025
Targeting Tumor-Associated Hypoxia with Bioreductively Activatable Prodrug Conjugates Derived from Dihydronaphthalene, Benzosuberene, and Indole-based Inhibitors of Tubulin PolymerizationZhe Shi, Rajsekhar Guddneppanavar, Blake A Winn, et al.
Cancers|September 9, 2022
Demonstrating Tumor Vascular Disrupting Activity of the Small-Molecule Dihydronaphthalene Tubulin-Binding Agent OXi6196 as a Potential Therapeutic for Cancer TreatmentLi Liu, Regan Schuetze, Jeni L Gerberich, et al.
Journal of Natural Products|March 21, 2020
Bioreductively Activatable Prodrug Conjugates of Combretastatin A-1 and Combretastatin A-4 as Anticancer Agents Targeted toward Tumor-Associated HypoxiaBlake A Winn, Laxman Devkota, Bunnarack Kuch, et al.
Cancers|March 13, 2025
Evaluating Therapeutic Efficacy of the Vascular Disrupting Agent OXi8007 Against Kidney Cancer in MiceHashini I Wanniarachchi, Regan Schuetze, Yuling Deng, et al.
Cancer Letters|September 2, 2015
The vascular disrupting activity of OXi8006 in endothelial cells and its phosphate prodrug OXi8007 in breast tumor xenograftsTracy E Strecker, Samuel O Odutola, Ramona Lopez, et al.
Journal of Natural Products|September 11, 2013
Synthesis of a 2-aryl-3-aroyl indole salt (OXi8007) resembling combretastatin A-4 with application as a vascular disrupting agentMallinath B Hadimani, Matthew T Macdonough, Anjan Ghatak, et al.
Magnetic Resonance in Medicine|September 21, 2022
The future of MRI in radiation therapy: Challenges and opportunities for the MR communityRosie J Goodburn, Marielle E P Philippens, Thierry L Lefebvre, et al.
International Journal of Radiation Biology|November 23, 2006
Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapyJames L Tatum, Gary J Kelloff, Robert J Gillies, et al.
Pageof 14

Showing results (131-140 of 139) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 139 results.
Journal of Magnetic Resonance Imaging : JMRI|March 30, 2019
Translating preclinical MRI methods to clinical oncologyDavid A Hormuth, Anna G Sorace, John Virostko, et al.
RSC Medicinal Chemistry|September 10, 2025
Targeting Tumor-Associated Hypoxia with Bioreductively Activatable Prodrug Conjugates Derived from Dihydronaphthalene, Benzosuberene, and Indole-based Inhibitors of Tubulin PolymerizationZhe Shi, Rajsekhar Guddneppanavar, Blake A Winn, et al.
Cancers|September 9, 2022
Demonstrating Tumor Vascular Disrupting Activity of the Small-Molecule Dihydronaphthalene Tubulin-Binding Agent OXi6196 as a Potential Therapeutic for Cancer TreatmentLi Liu, Regan Schuetze, Jeni L Gerberich, et al.
Journal of Natural Products|March 21, 2020
Bioreductively Activatable Prodrug Conjugates of Combretastatin A-1 and Combretastatin A-4 as Anticancer Agents Targeted toward Tumor-Associated HypoxiaBlake A Winn, Laxman Devkota, Bunnarack Kuch, et al.
Cancers|March 13, 2025
Evaluating Therapeutic Efficacy of the Vascular Disrupting Agent OXi8007 Against Kidney Cancer in MiceHashini I Wanniarachchi, Regan Schuetze, Yuling Deng, et al.
Cancer Letters|September 2, 2015
The vascular disrupting activity of OXi8006 in endothelial cells and its phosphate prodrug OXi8007 in breast tumor xenograftsTracy E Strecker, Samuel O Odutola, Ramona Lopez, et al.
Journal of Natural Products|September 11, 2013
Synthesis of a 2-aryl-3-aroyl indole salt (OXi8007) resembling combretastatin A-4 with application as a vascular disrupting agentMallinath B Hadimani, Matthew T Macdonough, Anjan Ghatak, et al.
Magnetic Resonance in Medicine|September 21, 2022
The future of MRI in radiation therapy: Challenges and opportunities for the MR communityRosie J Goodburn, Marielle E P Philippens, Thierry L Lefebvre, et al.
International Journal of Radiation Biology|November 23, 2006
Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapyJames L Tatum, Gary J Kelloff, Robert J Gillies, et al.
Pageof 14